Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.
Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V, Maughan BL, Pili R, Adra N, Sternberg CN, Vlachostergios PJ, Tagawa ST, Bryce AH, McNatty AL, Reichert ZR, Dreicer R, Sartor O, Lotan TL, Hussain M. Antonarakis ES, et al. Among authors: isaacsson velho p. JCO Precis Oncol. 2020;4:370-381. doi: 10.1200/po.19.00399. Epub 2020 Apr 21. JCO Precis Oncol. 2020. PMID: 32462107 Free PMC article.
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.
Isaacsson Velho P, Antonarakis ES. Isaacsson Velho P, et al. Expert Rev Clin Pharmacol. 2018 May;11(5):475-486. doi: 10.1080/17512433.2018.1464388. Epub 2018 Apr 24. Expert Rev Clin Pharmacol. 2018. PMID: 29641940 Free PMC article. Review.
Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M, Fang M, H Marshall C, Lotan TL, Isaacsson Velho P, Antonarakis ES. Nakazawa M, et al. Among authors: isaacsson velho p. Prostate. 2022 Feb;82(2):260-268. doi: 10.1002/pros.24269. Epub 2021 Nov 15. Prostate. 2022. PMID: 34783071 Free PMC article.
Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer.
Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N. Swami U, et al. Among authors: isaacsson velho p. Eur Urol. 2020 Nov;78(5):652-656. doi: 10.1016/j.eururo.2020.06.033. Epub 2020 Jul 2. Eur Urol. 2020. PMID: 32624276 Free PMC article.
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
Sena LA, Fountain J, Isaacsson Velho P, Lim SJ, Wang H, Nizialek E, Rathi N, Nussenzveig R, Maughan BL, Velez MG, Ashkar R, Larson AC, Pritchard CC, Adra N, Bryce AH, Agarwal N, Pardoll DM, Eshleman JR, Lotan TL, Antonarakis ES. Sena LA, et al. Among authors: isaacsson velho p. Oncologist. 2021 Feb;26(2):e270-e278. doi: 10.1002/onco.13601. Epub 2020 Dec 3. Oncologist. 2021. PMID: 33215787 Free PMC article.
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, Shaukat F, Carducci MA, Denmeade SR, Paller CJ, Markowski MC, Marshall CH, Eisenberger MA, Antonarakis ES. Isaacsson Velho P, et al. Eur Urol. 2020 Jan;77(1):14-21. doi: 10.1016/j.eururo.2019.05.032. Epub 2019 Jun 5. Eur Urol. 2020. PMID: 31176623 Free PMC article.
30 results